BriaCell Therapeutics Corp. stock is down -20.33% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 13 February’s closed higher than January. In the last 3 Unusual Options Trades, there were 2 CALLs, 1 PUT.
BriaCell Therapeutics Corp. engages in developing immunotherapies for the treatment of cancer. Lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors. Company also has a cooperative research and development agreement with the National Cancer Institute.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!